FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

View source ↗

Summary

FDA approved a supplemental application for TYSABRI (Natalizumab) filed by Biogen Inc. The action represents an approved regulatory update to the product labeli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

SUPPL AP for TYSABRI (NATALIZUMAB)